AVBP
What one share of Arrivent Biopharma holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers.
Arrivent Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.69 |
|---|---|
| Cash and investments | $3.20 |
| Book value | $7.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$32.38 | — | −$26.08 | — | −$55.80 |
| 2024 | — | −$2.56 | — | −$2.23 | — | $7.64 |
| 2025 | — | −$4.32 | — | −$4.18 | — | $7.24 |